Varian To Pay $1.3bn For Interventional Oncology Specialist Sirtex
Executive Summary
Radiation oncology firm Varian believes Sirtex will allow it to expand into additional areas of cancer treatment.
You may also be interested in...
Varian Grows Cancer Portfolio With Endocare & Alicon Acquisitions
Varian is expanding its cancer care solutions portfolio with two new acquisitions in the interventional oncology space. The medtech giant said it will pay $185m to buy Endocare Systems, based in Austin, Texas; and Alicon, based in Hangzhou, China.
Device/Diagnostics Quarterly Deal-Making Statistics, Q1 2018
Device fundraising in the first quarter totaled $7.6 billion, thanks to Siemens Healthineers $5.2 billion IPO, which accounted for more than two-thirds of the total. Q1 M&A activity reached $6.7 billion, a significant rise from Q4's $3.9 billion. Similarly, aggregate first quarter diagnostics financings (at $1.5 billion) and M&As (at $543 million) also experienced substantial increases over the previous quarter.
Varian Stands Firm Against Rival Bid For SirTex; What Next If It All Falls Down?
Varian Medical Systems' proposed $1.3bn deal to acquire SirTex Medical is officially in jeopardy after China's CDH Investments formalized its rival bid to snatch away the Australian interventional oncology firm. Should the deal fall through, what would Varian's next steps be?